Conversation With New CEO Encourages
Yesterday we had a 30-minute conversation with InVivo Therapeutics' (OTCQB:NVIV) new CEO, Michael J. Astrue. Mr. Astrue took over as head of InVivo back in late August 2013 when former CEO, CFO, and Chairman, Francis M. Reynolds, resigned for an undisclosed medical condition. What exactly the medical condition was that caused Mr. Reynolds to resign, or whether or not he was effectively forced out by the board and disgruntled shareholders, remains a mystery to outsiders. However, worth noting, only a few weeks later, acting CFO, Sean F. Moran, also resigned. Gregory D. Perry was appointed interim CFO in mid-September 2013. Below we provide a brief background for both Mr. Astrue...
Only subscribers can access this article, which is part of the PRO research library covering 3,577 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: